Acrivon Therapeutics, Inc. (ACRV)
(Delayed Data from NSDQ)
$7.95 USD
-0.16 (-1.97%)
Updated May 24, 2024 04:00 PM ET
After-Market: $7.92 -0.03 (-0.38%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
ACRV 7.95 -0.16(-1.97%)
Will ACRV be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ACRV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACRV
5 Small Drug Stocks to Buy From a Recovering Industry
Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?
ACRV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?
Catalyst (CPRX) to Report Q1 Earnings: What's in the Cards?
Other News for ACRV
Acrivon Therapeutics: A Buy Rating on Strong Clinical and Financial Prospects
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics price target raised by $2 at H.C. Wainwright, here's why
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), Arcutis Biotherapeutics (ARQT) and TruBridge (TBRG)